A randomized comparison of the Combo Dual Therapy Stent, from Orbus Neich, which combines low-dose sirolimus delivery from an abluminal...
Orbus Neich has announced long-term results from its REMEDEE Trial of the COMBO Dual Therapy Stent for patients with Coronary...
OrbusNeich has reported results from the REDUCE trial demonstrating optimal treatment of patients with acute coronary syndrome (ACS) using the...
Data from the REMEDEE study of the COMBO Dual Therapy Stent, from Orbus Neich, demonstrated that the stent met the...
AbbVie submitted marketing authorization applications (MAAs) to the European Medicines Agency (EMA) seeking approval for the all-oral, interferon-free regimen ABT...
Janssen-Cilag International has submitted a Marketing Authorisation Application to the European Medicines Agency seeking approval for a once-daily single tablet...
Merck Inc announced the European Medicines Agency has accepted for review a marketing authorization application for grazoprevir/elbasvir (100mg/50mg), an investigational,...
Gilead Sciences has announced topline results from a Phase III clinical trial (GS-US-337-0113) in Japan evaluating the once-daily fixed-dose combination...
The FDA has approved Olysio (simeprevir) in combination with Sovaldi (sofosbuvir), from Medivir and Janssen, as an all-oral, interferon- and...
Two phase III clinical trials found the investigational combination tablet of empagliflozin and linagliptin, from Boehringer and Eli Lilly, reduced...